Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light

Transfusion

Volumn 56, Issue 6, 2016, Pages 1548-1555

  Faddy, Helen M ^a,b   Fryk, Jesse J ^a   Prow, Natalie A ^b,c   Watterson, Daniel ^b   Young, Paul R ^b   Hall, Roy A ^b   Tolksdorf, Frank ^d   Sumian, Chryslain ^e   Gravemann, Ute ^f   Seltsam, Axel ^f   Marks, Denese C ^a  

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d MacoPharma International GmbH   (Germany)

^e MacoPharma   (France)

^f Institute Springe   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; THROMBOCYTE CONCENTRATE; VIRUS ANTIBODY;

ALPHAVIRUS INFECTION; ANTIBODY DETECTION; ARTICLE; BLOOD BUFFY COAT; CHIKUNGUNYA; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; HUMAN; NONHUMAN; RADIATION DOSE; ROSS RIVER VIRUS; ROSS RIVER VIRUS INFECTION; ULTRAVIOLET C RADIATION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS STRAIN; BLOOD SAFETY; CHIKUNGUNYA VIRUS; DENGUE VIRUS; LIMIT OF DETECTION; PROCEDURES; RADIATION RESPONSE; RNA VIRUS; STANDARDS; THROMBOCYTE; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION; VIROLOGY;

BLOOD PLATELETS; BLOOD SAFETY; CHIKUNGUNYA VIRUS; DENGUE VIRUS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LIMIT OF DETECTION; PLATELET TRANSFUSION; RNA VIRUSES; ROSS RIVER VIRUS; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 84974534194     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13519     Document Type: Article

References (46)

1. Petersen LR, Busch MP., Transfusion-transmitted arboviruses. Vox Sang 2010; 98: 495-503.
2. Stramer SL, Linnen JM, Carrick JM, et al., Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012; 52: 1657-66.
3. Petersen LR, Stramer SL, Powers AM., Chikungunya virus: possible impact on transfusion medicine. Transfus Med Rev 2010; 24: 15-21.
4. Hoad VC, Speers DJ, Keller AJ, et al., First reported case of transfusion-transmitted Ross River virus infection. Med J Aust 2015; 202: 267-70.
5. Bhatt S, Gething PW, Brady OJ, et al., The global distribution and burden of dengue. Nature 2013; 496: 504-7.
6. Viennet E, Ritchie SA, Faddy HM, et al., Epidemiology of dengue in a high-income country: a case study in Queensland, Australia. Parasit Vectors 2014; 7: 379.
7. Hayden MH, Cavanaugh JL, Tittel C, et al., Post outbreak review: dengue preparedness and response in Key West, Florida. Am J Trop Med Hyg 2015;93:397-400.
8. Yung CF, Lee KS, Thein TL, et al., Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, Singapore. Am J Trop Med Hyg 2015; 92: 999-1005.
9. Roth A, Hoy D, Horwood PF, et al., Preparedness for threat of chikungunya in the Pacific. Emerg Infect Dis 2014; 20:
10. Kendrick K, Stanek D, Blackmore C., Notes from the field: transmission of chikungunya virus in the continental United States-Florida, 2014. MMWR Morb Mortal Wkly Rep 2014; 63: 1137.
11. Nunes MR, Faria NR, de Vasconcelos JM, et al., Emergence and potential for spread of chikungunya virus in Brazil. BMC Med 2015; 13: 102.
12. Weaver SC, Lecuit M., Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015; 372: 1231-9.
13. Knope KE, Doggett SL, Kurucz N, et al., Arboviral diseases and malaria in Australia, 2011-12: annual report of the National Arbovirus and Malaria Advisory Committee. Commun Dis Intell Q Rep 2014; 38: E122-42.
14. Tesh RB, Gajdusek DC, Garruto RM, et al., The distribution and prevalence of group A arbovirus neutralizing antibodies among human populations in Southeast Asia and the Pacific islands. Am J Trop Med Hyg 1975; 24: 664-75.
15. Tesh RB, McLean RG, Shroyer DA, et al., Ross River virus (Togaviridae: Alphavirus) infection (epidemic polyarthritis) in American Samoa. Trans R Soc Trop Med Hyg 1981; 75: 426-31.
16. Klapsing P, MacLean JD, Glaze S, et al., Ross River virus disease reemergence, Fiji, 2003-2004. Emerg Infect Dis 2005; 11: 613-5.
17. Aubry M, Finke J, Teissier A, et al., Silent circulation of Ross River virus in French Polynesia. Int J Infect Dis 2015; 37: 19-24.
18. Chuang V, Wong TY, Leung YH, et al., Review of dengue fever cases in Hong Kong during 1998 to 2005. Hong Kong Med J 2008; 14: 170-7.
19. Tambyah PA, Koay ES, Poon ML, et al., Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med 2008; 359: 1526-7.
20. Oh HB, Muthu V, Daruwalla ZJ, et al., Bitten by a bug or a bag? Transfusion-transmitted dengue: a rare complication in the bleeding surgical patient. Transfusion 2015; 55: 1655-61.
21. Levi JE, Nishiya A, Felix AC, et al., Real-time symptomatic case of transfusion-transmitted dengue. Transfusion 2015; 55: 961-4.
22. Sabino EC., Transfusion-transmission of dengue virus and associated clinical symptomatology during the 2012 epidemic in Brazil. J Infect Dis 2015. doi: 10.1093/infdis/jiv326.
23. Faddy HM, Seed CR, Fryk JJ, et al., Implications of dengue outbreaks for blood supply, Australia. Emerg Infect Dis 2013; 19: 787-9.
24. Rasonglès P, Angelini-Tibert MF, Simon P, et al., Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009; 49: 1083-91.
25. Gallian P, de Lamballerie X, Salez N, et al., Prospective detection of chikungunya virus in blood donors, Caribbean 2014. Blood 2014; 123: 3679-81.
26. Faddy H, Dunford M, Seed C, et al., Seroprevalence of antibodies to Ross River and Barmah Forest Viruses: possible implications for blood transfusion safety after extreme weather events. Ecohealth 2014;12:347-53.
27. Solheim BG., Pathogen reduction of blood components. Transfus Apher Sci 2008; 39: 75-82.
28. Marks DC, Faddy HM, Johnson L., Pathogen reduction technologies. ISBT Sci Ser 2014; 9: 44-50.
29. Mohr H, Steil L, Gravemann U, et al., A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49: 2612-24.
30. Seltsam A, Muller TH., UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38: 43-54.
31. Steinmann E, Gravemann U, Friesland M, et al., Two pathogen reduction technologies-methylene blue plus light and shortwave ultraviolet light-effectively inactivate hepatitis C virus in blood products. Transfusion 2013; 53: 1010-8.
32. Johnson L, Winter KM, Reid S, et al., The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101: 208-14.
33. Bertolini F, Agazzi A, Peccatori F, et al., The absence of swirling in platelet concentrates is highly predictive of poor posttransfusion platelet count increments and increased risk of a transfusion reaction. Transfusion 2000; 40: 121-2.
34. Faddy HM, Prow NA, Fryk JJ, et al., The effect of riboflavin and ultraviolet light on the infectivity of arboviruses. Transfusion 2015; 55: 824-31.
35. Frentiu FD, Robinson J, Young PR, et al., Wolbachia-mediated resistance to dengue virus infection and death at the cellular level. PLoS One 2010; 5: e13398.
36. Doherty RL, Whitehead RH, Gorman BM, et al., The isolation of a third group A arbovirus in Australia, with preliminary observations on its relationship to epidemic polyarthritis. Aust J Sci 1963; 26: 183.
37. Watterson D, Kobe B, Young PR., Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. J Gen Virol 2012; 93: 72-82.
38. Appendix 3: Probability of detection of viruses at low concentrations. In: ICH Topic Q5A (R1) viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. London: European Medicine Agency; 1997. p. 29.
39. Appendix 3: Probability of detection of viruses at low concentrations. In: Guidance for industry: Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Washington (DC): U.S. Department of Health & Human Services, Food and Drug Administration. 1998. p. 28.
40. Custer B, Agapova M, Martinez RH., The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010; 50: 2461-73.
41. Sandgren P, Tolksdorf F, Struff WG, et al., In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-platelets method. Vox Sang 2011; 101: 35-43.
42. Bashir S, Cookson P, Wiltshire M, et al., Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 2013; 53: 990-1000.
43. Marrocco C, D'Alessandro A, Girelli G, et al., Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. Transfusion 2013; 53: 1808-20.
44. Johnson L, Hyland R, Tan S, et al., In vitro quality of platelets with low plasma carryover treated with ultraviolet C light for pathogen inactivation. Transfus Med Hemother. doi: 10.1159/000441830.
45. Pohler P, Lehmann J, Veneruso V, et al., Evaluation of the tolerability and immunogenicity of ultraviolet C-irradiated autologous platelets in a dog model. Transfusion 2012; 52: 2414-26.
46. Thiele T, Pohler P, Kohlmann T, et al., Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction - a phase I clinical trial. Vox Sang 2015; 109: 44-51.